DocCheck AG (AJ91) AI Stock Analysis

• Market Cap: €65.94M
• Dividend Yield: 5.53%
• Average Volume (3M): 1.04K
• Price to Earnings (P/E): 11.2
• Beta (1Y): 0.70
• Revenue Growth: 8.24%
• EPS Growth: 140.53%
• Country: DE
• Employees: 373
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.48
• Shares Outstanding: 5,033,876
• 10 Day Avg. Volume: 577
• 30 Day Avg. Volume: 1,041
• PEG Ratio: 0.06
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.79
• P/FCF Ratio: 6.21
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €13.00
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: €13.00 ▲(0.00% Upside)

DocCheck AG's overall stock score is driven by its strong financial performance and attractive valuation. The company's solid profitability and efficient cash flow management are significant strengths. However, technical indicators suggest a bearish short-term trend, which slightly offsets the positive valuation metrics.

DocCheck AG Business Overview & Revenue Model

Company Description

DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.

How the Company Makes Money

DocCheck AG generates revenue through multiple streams, primarily from subscription fees, advertising, and partnerships with pharmaceutical companies. The company's subscription model allows healthcare professionals to access premium content and tools, creating a steady income source. Additionally, DocCheck earns revenue from targeted advertising aimed at its professional audience, leveraging its extensive user base to attract advertisers within the healthcare sector. Strategic partnerships with pharmaceutical companies further bolster its revenue, as these partnerships often involve co-branded initiatives, sponsored content, and marketing campaigns that align with the interests of healthcare providers. Overall, DocCheck's diversified revenue model ensures its financial stability and growth within the competitive online healthcare space.

DocCheck AG Financial Statement Overview

Summary

DocCheck AG displays strong profitability with a solid gross profit margin of 19.6% and a net profit margin of 9.8%. The EBIT margin improved significantly, indicating enhanced operational efficiency. However, declining total revenue and assets pose potential challenges to future profitability and financial stability.

Income Statement

DocCheck AG's income statement shows strong profitability with a gross profit margin of 19.6% and a net profit margin of 9.8% for the latest annual period. Revenue growth has been relatively stable, with a modest increase of 0.7% from the previous year. The EBIT margin improved substantially to 12.0% from 6.6%, indicating enhanced operational efficiency. However, there is a concern over the company's declining total revenue over the last few years, which may impact future profitability.

Balance Sheet

The balance sheet of DocCheck AG reflects a solid financial position with a low debt-to-equity ratio of 0.12, suggesting conservative leverage. The equity ratio stands at 65.9%, indicating a strong equity base relative to total assets. Return on equity is healthy at 13.2%, showcasing efficient use of equity capital. However, declining total assets and stockholders' equity in recent periods may pose potential risks to long-term financial stability.

Cash Flow

The cash flow statement highlights a robust operating cash flow to net income ratio of 1.48, demonstrating strong cash generation relative to net income. Free cash flow increased by 21.3% year-over-year, reflecting effective cash management. The company maintains a positive free cash flow to net income ratio of 1.29, underscoring its ability to generate surplus cash after capital expenditures. Nevertheless, fluctuations in free cash flow over recent years warrant monitoring.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.79M	53.41M	60.90M	85.92M	63.10M
Gross Profit	10.53M	12.97M	14.08M	21.54M	18.26M
EBITDA	10.18M	9.38M	13.38M	20.09M	15.90M
Net Income	5.28M	2.27M	6.29M	11.40M	9.20M
Balance Sheet
Total Assets	60.86M	56.14M	63.28M	60.25M	46.99M
Cash, Cash Equivalents and Short-Term Investments	21.02M	17.52M	15.66M	21.52M	19.99M
Total Debt	5.01M	5.85M	7.07M	7.03M	1.61M
Total Liabilities	20.78M	18.11M	23.86M	22.08M	15.64M
Stockholders Equity	40.08M	37.33M	38.57M	37.31M	30.91M
Cash Flow
Free Cash Flow	6.82M	5.62M	-557.91K	6.90M	9.15M
Operating Cash Flow	7.82M	7.51M	5.89M	10.92M	12.57M
Investing Cash Flow	-1.48M	-1.93M	-4.92M	-4.39M	-936.57K
Financing Cash Flow	-3.50M	-4.60M	-5.81M	-5.86M	-1.08M

DocCheck AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Neutral. The current price of 13 is below the 20-day moving average (MA) of 13.04, above the 50-day MA of 12.55, and above the 200-day MA of 10.91, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 52.98 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:AJ91.

DocCheck AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	€45.14M	10.49	24.14%	3.83%	-5.72%	-25.19%
AJ91	72 Outperform	€65.94M	11.24	15.57%	5.53%	8.24%	140.53%
NXU	67 Neutral	€1.23B	35.94	12.38%	0.32%	6.72%	33.84%
COP	62 Neutral	€1.25B	66.95	2.87%	0.21%	1.16%	-43.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
V3V	41 Neutral	€103.72M	27.28	-53.67%	―	11.30%	-3316.77%